

1 **N-Palmitoyl glycine activates transient receptor potential**
2 **channel 5 and increases the risk of Brugada syndrome**

3

4 **Running title:** N-Palmitoylglycine and TRPC5 in Brugada syndrome

5

6 Hongxuan Xu, PhD^{1,2*}, Bingxun Li, PhD^{1,2*}, Ying Chen, PhD^{1,2}, Yanyun Lin, PhD^{1,2},

7 An Zhang, PhD^{1,2}, and Lin Wu, MD^{1,2,3#}

8

9 ¹ Department of Cardiology, Peking University First Hospital, Beijing, China.

10 ² State Key Laboratory of Vascular Homeostasis and Remodeling, Peking University

11 ³ Key Laboratory of Medical Electrophysiology of Ministry of Education, Institute of

12 Cardiovascular Research, Southwest Medical University, Luzhou, China.

13

14 #Corresponding author: Lin Wu; E-mail: wuepgroup@126.com; address: NO.8

15 Xishiku Street, Department of Cardiology, Peking University First Hospital, Beijing,

16 China.

17

18 *These authors contributed equally to this study.

19

20 **Abstract**

21 **Background**

22 Brugada syndrome (BrS) is an arrhythmic disorder associated with an increased risk of sudden
23 cardiac death; however, current treatment options are limited due to their side effects and variable
24 efficacy.

25 **Methods**

26 In this study, we first employed Mendelian randomization analysis utilizing proteomic,
27 transcriptomic, and metabolomic data to identify potential therapeutic targets for BrS. Ex vivo
28 perfused heart models were used to assess the effects of the potential targets on action potentials
29 and QT intervals. Calcium indicators were employed to evaluate calcium homeostasis in primary
30 cardiomyocytes, and patch-clamp techniques were used to investigate the impact on Nav1.5 and
31 TRPC5 channels.

32 **Results**

33 Our findings indicate that N-palmitoyl glycine (PalGly) is linked to an increased risk of BrS and
34 interacts with BrS-associated proteins, demonstrating moderate binding affinities for DCC, CR1,
35 CTSB, NAAA, DEFB1, EPHA1, IGF1/IGFBP3/ALS, and LTA. Electrophysiological experiments
36 showed that although PalGly does not interact with Nav1.5, it enhances calcium sparks in
37 ventricular cardiomyocytes. We determined that the calcium-modulating effect of PalGly is
38 mediated by its binding to and activation of the transient receptor potential channel 5 (TRPC5)
39 channel. Furthermore, PalGly was found to shorten the QT interval and action potential duration
40 in Langendorff-perfused rabbit hearts and isolated rabbit cardiomyocytes. Transcriptomic and
41 lipidomic analyses of PalGly-treated neonatal rat cardiomyocytes revealed significant negative

42 modulation of immune pathways, akin to the effects observed with agonizing TRPC5.

43 **Conclusion**

44 Our study underscores the involvement of PalGly, TRPC5, and inflammation-related proteins in

45 the pathophysiology of BrS.

46

47

48 **Introduction**

49 Brugada syndrome (BrS) is a rare arrhythmic disorder with an increased risk of sudden death,
50 characterized by hallmark ST-segment elevation in the right precordial leads of the
51 electrocardiogram (ECG)¹. BrS is traditionally considered an inherited channelopathy with a
52 Mendelian autosomal dominant pattern. However, the penetrance and causative effect of reported
53 BrS-related genetic variants is often uncertain. The phenotypes of one variant can be discordance
54 between probands and their family members². Current treatments for BrS including antiarrhythmic
55 medication, implantable cardioverter-defibrillator (ICD), and catheter ablation are limited by their
56 side effects and effectiveness³. Especially for asymptomatic patients who present typical BrS
57 pattern ECG, these strategies are far from optimal to prevent a likely fatal incidence. In this study,
58 we first use Mendelian randomization (MR) analysis based on proteomics, transcriptomics, and
59 metabolomics to explore potential causal targets for BrS, and then we test our findings with in
60 vitro and ex vivo electrophysiological experiments.

61 **Methods**

62 **BrS cohort and ECG-wide association study**

63 Summary-level statistics for BrS were obtained from a meta-analysis study comprising 2,820
64 unrelated cases and 10,001 controls of European ancestry⁴. The diagnosis followed the guidelines
65 from the 2013 Heart Rhythm Society, European Heart Rhythm Association and Asia Pacific Heart
66 Rhythm Society expert consensus statement⁵, the 2015 European Society of Cardiology
67 guidelines⁶ and the 2017 American Heart Association guidelines⁷. Inclusion criteria required a type

68 1 BrS ECG, characterized by coved-type ST elevation at baseline (spontaneous) or after a drug
69 challenge test, in one or more leads of the right precordial leads (V1 and/or V2), either in the
70 standard (fourth intercostal space) or higher positions (second or third intercostal spaces).
71 Diagnostic ECGs were centrally reviewed by a cardiac electrophysiologist experienced in BrS to
72 confirm that the diagnostic criteria were met. The genetic associations were adjusted for the first
73 six genetic principal components, SNPs that were missing in four or more of the ten strata, as well
74 as those with a heterogeneity test $P < 1e-6$ were excluded. Top variants of significant exposures
75 were looked up in ECGenetics (<http://www.ecgenetics.org>)⁸ to explore their effect on R-R
76 adjusted three-lead exercise electrocardiogram (ECG) morphology. The GWAS for ECG
77 morphology consists of comprehensive deep phenotyping of 77,190 ECGs in the UK Biobank
78 across the complete cycle of cardiac conduction, resulting in 500 spatial-temporal data points.
79 Summary-level statistics for QTc consists of 84 630 UK Biobank participants⁹.

80 **Multi-omics GWAS data source**

81 Summary-level statistics of genome-wide association studies (GWAS) for two protein quantitative
82 trait loci (pQTL) studies were obtained from deCode genetics¹⁰ and UKB-PPP¹¹. Proteomics from
83 deCode genetics consists of 4,907 circulating proteins in 35,559 Icelanders measured by
84 SOMAscan version 4. Proteomics from UKB-PPP consists of 2,923 circulating proteins measured
85 by Olink technology in 54,219 UK Biobank participants with the most European ancestry (around
86 95%). The protein level of these two studies was inverse rank normalized to perform
87 covariates-adjusted genetic association. In addition, eQTL data was obtained from the eQTLgen
88 Consortium which measured transcriptomics by arrays and RNA-seq from 311,684 blood and

89 PBMC (peripheral blood mononuclear cell) samples (Predominantly European ancestry)¹².
90 Summary-level statistics of genetic associations with inverse rank normalized levels of 1,091
91 blood metabolites and 309 metabolite ratios quantified by the Metabolon HD4 platform in 8,299
92 unrelated European ancestry individuals from the Canadian Longitudinal Study on Aging (CLSA)
93 cohort¹³ were obtained.

94 **Cardiometabolic traits**

95 A total of 28 cardiometabolic traits were included, including lipids (total cholesterol, triglycerides,
96 high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C),
97 apolipoprotein A1 and B (ApoA1, ApoB), and lipoprotein A Lp(a))^{14,15}, blood pressure (systolic
98 blood pressure (SBP), and diastolic blood pressure (DBP))¹⁶, glycemic traits (fasting glucose,
99 fasting insulin, 2-hour post-challenge glucose, and HbA1c)^{17,18}, and anthropometric traits (body
100 mass index (BMI), waist circumference, hip circumference, and waist-to-hip ratio)¹⁹. With 11
101 cardiometabolic diseases, including atrial fibrillation (AF), stroke and stroke subtypes (large artery
102 atherosclerosis, small-vessel, and cardioembolic)²⁰, coronary heart disease (CHD)²¹, heart failure
103 (HF)²², aortic aneurysms²³, chronic kidney disease²⁴, type 1 diabetes²⁵ and type 2 diabetes²⁶. Most
104 participants in these cohorts were of European ancestry (Table S1).

105 **Exposure instrument variables selection**

106 Genome-wide suggestive SNPs ($p < 1e-6$) in weak linkage disequilibrium ($r^2 < 0.1$, based on the
107 1000 Genomes Phase 3 European reference panel) within ± 1 Mb from target gene loci associated
108 with the proteins were obtained. Independent effect SNPs for metabolites QTL were identified by
109 genome-wide suggestive threshold ($p < 1e-6$) and were clumped by a 1Mb distance with a linkage

110 disequilibrium threshold $r^2 = 0.1$. Clumping was performed by Plink version 1.9²⁷. F-statistics of
111 less than ten were used to exclude SNPs that were weak instruments for a limited proportion of the
112 variance explained.

113 **MR analysis**

114 The included cohorts consist of almost European ancestry, no individuals likely to overlap.
115 Two-sample MR analysis based on indexed SNPs for circulating proteins, RNAs, and metabolites
116 was used to capture the associations with the risk of BrS. An inverse variance weighted (IVW)
117 random-effects model was employed to estimate the causal effects of genetically proxied targets
118 on BrS. Bonferroni correction was used to account for multiple tests. Weighted median, MR Egger
119 and Steiger test were used to employ sensitivity analysis, heterogeneity test, and causal direction
120 test. All MR analyses were performed in R version 4.3.2 by TwoSampleMR package²⁸. Findings
121 were reported according to the STROBE-MR (Strengthening the Reporting of Mendelian
122 Randomization Studies) guidelines²⁹.

123 **Colocalization analysis**

124 Colocalization analysis was employed by the coloc R package³⁰ to test whether identified
125 exposures and BrS were associated and shared the same causal variant within ± 1 Mb from target
126 gene loci associated with the proteins. We set prior probabilities of the SNP being only associated
127 with exposure (p1) or outcome (p2) at $1e-4$; and the probability of the SNP being associated with
128 both traits (p12) at $1e-5$, posterior probability for shared causal variants (PPH4) ≥ 0.8 were
129 considered to have strong evidence of colocalization. The set of significant genes and proteins
130 with high colocalization support was set forth to an overrepresentation analysis using the

131 pathways described in the Gene Ontology and the KEGG database. Selected pathways were those
132 significantly enriched at an FDR <0.05.

133 **Mediation analysis**

134 We explored the mediation effect of circulating proteins on BrS via metabolites using the delta
135 method to approximate confidence intervals by the RMediation package³¹. The MR estimate for
136 the mediated effect of genetically predicted levels of circulating metabolites on BrS was divided
137 by the total effect of genetically predicted levels of circulating proteins on BrS risk estimated in
138 the IVW univariable MR, with standard errors estimated using the propagation of error method to
139 calculate mediation proportion.

140 **Molecular Docking**

141 The 3D structures of DCC, CR1, CTSB, NAAA, DEFB1, EPHA1, IGF1/IGFBP3/ALS, and LTA
142 were obtained from RCSB Protein Data Bank (PDB ID: 2ED7, 2ED8, 2ED9, 2EDB, 2EDD,
143 2EDE, 2MCY, 2MCZ, 3AI8, 1HUC, 6DXW, 6DXX, 1IJV, 2K1K, 2K1L, 7WRQ, 4MXV, 4MXW)
144 and was subjected to processing through the pdb2pqr before initiating the docking analysis. The
145 entire docking process was conducted using Autodock vina 1.2.0 by Dockey graphical interface³²
146 with default parameters. The visualization was performed by PyMOL 3.0.3.

147 **Isolation of rabbit cardiomyocytes**

148 Rabbit ventricular cardiomyocytes were isolated enzymatically, as previously described³³. The
149 animal used in this study conformed to the “Guide for the Care and Use of Laboratory Animals”
150 published by the US National Institutes of Health (NIH Publication No. 85-23, revised 2011). The

151 ethical clearance was granted by the Institutional Animal Care and Use Committee of Peking
152 University First Hospital (approved number: J2024090), affirming the conscientiousness of their
153 treatment and welfare. Male New Zealand rabbits weighing 2.5 to 3.0 kg (approximately
154 3-month-old, Fangyuanyuan, China) were anaesthetized with xylazine (16 mg/kg, Huamu; China)
155 and ketamine (40 mg/kg CAHG; China) (IV) and injected with 5,000 units/kg of heparin. The
156 absence of pain response and corneal reflex served as the indicators to ascertain the appropriate
157 level of anaesthesia depth. Rabbit hearts were rapidly excised and retrogradely perfused through
158 the aorta on a standard Langendorff apparatus for 10 min at a flow rate of 10 mL/min with a
159 calcium-free Tyrode solution continuously gassed with 100% O₂ at 37 °C. The hearts were
160 perfused in a recirculating manner for 40–60 min (ventricular cardiomyocytes) with 100 mL of
161 calcium-free Tyrode solution containing 60 mg of collagenase (type II, Sigma) and 100 mg of
162 bovine serum albumin (BSA, Sigma). The enzymes were washed out for 5 min via perfusion with
163 a calcium-free Tyrode solution. The ventricles were cut into small chunks, and the tissue was
164 manually pipetted with a disposable plastic transfer pipette for 1-2 min to mechanically separate
165 the cells. The cell and enzyme mixture were filtered through a 200-micron nylon mesh into
166 centrifuge tubes and the cells were stored in KB solution. Cells of approximately the same length
167 and with clear stripes, a rod shape, a clean and smooth surface, and no spontaneous contractions
168 over 1 minute of observation were selected for use in the experiments. The animal use was
169 approved by the Institutional Animal Care and Use Committee of Peking University First Hospital.
170 The isolated cardiomyocytes were then incubated with N-palmitoyl glycine (MedChemExpress)
171 for at least 15 min to study its effect on action potential and calcium spark.

172 **Isolated Rabbit Heart Assay**

173 Following the excision, the heart was carefully removed and perfused with a specially modified
174 Krebs–Heinsleit (K–H) perfusate (pH 7.4, gassed with 95% O₂ and 5% CO₂) that was prewarmed
175 to 37 °C at a controlled speed of 20 mL/min after the aorta was cannulated. The K–H solution
176 contained (in mM) 118 NaCl, 2.8 KCl, 1.2 KH₂PO₄, 2.5 CaCl₂, 0.5 MgSO₄, 2.0 sodium pyruvate,
177 5.5 glucose, 0.57 Na₂EDTA, and 25 NaHCO₃. To ensure successful electrical pacing, the right
178 atrium was partially removed and the whole atrioventricular block was induced by
179 thermo-ablating the atrioventricular nodal area. A custom-made bipolar Teflon-coated electrode
180 was placed on the right ventricular septum to pace the heart. Electrical stimuli, 3 ms in width and
181 3-fold threshold amplitude were delivered to the pacing electrode at a frequency of 1 Hz using an
182 EP-4 stimulator (EP MedSystems, ST. JUDE MEDICAL). After ventricular pacing was initiated, a
183 30-minute period was allowed for the equilibration of heart rhythm to achieve a stable and
184 consistent rhythm before the subsequent measurements or interventions. Pressure-contact Ag–
185 AgCl MAP electrodes were placed on the epicardial and endocardial ventricular walls,
186 respectively. The ventricular MAP and pseudo-ECG were continuously monitored, amplified,
187 filtered, and digitized in real-time using a BIOPAC Systems MP 150 signal processor and
188 displayed on a computer screen using the AcqKnowledge 4.2 for MP150 software (BIOPAC
189 Systems, Inc.). The duration of the monophasic action potential at 30, 50, and 90% repolarization
190 (MAPD30/50/90) was used to monitor left ventricular repolarization. The MAPD30/50/90 was
191 measured at the steady state following the PalGly perfusion.

192 **Whole-Cell Voltage-Clamp Recordings of Na_v1.5 Channels** 193 **in HEK293T Cells**

194 The HEK293T cells were grown in culture dishes for 24 h, and plasmids expressing Na_v1.5
195 (NM_198056) were transfected into HEK293T (National Collection of Authenticated Cell
196 Cultures, China) cells using lipofectamine 3000 (Thermo Fisher Scientific). The extracellular
197 Solution (mM) contained: 137 NaCl, 1 MgCl₂·6H₂O, 4 KCl, 1.8 CaCl₂·2H₂O, 10 D-Glucose, 10
198 mM HEPES, adjusted to pH 7.4 with NaOH. The intracellular Solution (mM) contained: 50 CsCl,
199 60 CsF, 10 HEPES, 20 EGTA, and 10 NaCl, adjusted to pH 7.2 with CsOH. Patchmaster software,
200 coupled with an EPC-10 amplifier (EPC-10, Heka Electronic, Germany), was used to collect and
201 store electrophysiological data. Electrodes (1-3 MΩ) were pulled from 1.5-mm borosilicate glass
202 filaments using a P1000 micropipette puller. The holding potential was set at -120 mV, with a
203 series of square-wave pulses from -120 to -10 mV in 10 mV increments for 8000 ms, followed by
204 a step to -10 mV for 30 ms, and then returning to -120 mV. The data were fitted to the Boltzmann
205 equation to derive the steady-state inactivation curve. The holding potential was set at -120 mV,
206 followed by depolarization to 0 mV for 20 ms to stimulate the resting-state sodium channel
207 current. The voltage was then stepped to the condition pulse voltage corresponding to the
208 half-inactivation voltage ($V_{1/2}$) for 8000 ms, followed by repolarization to -120 mV for 30 ms.
209 Subsequently, depolarization to 0 mV for 20 ms stimulated the half-inactivated state sodium
210 channel current. Finally, the potential was returned to -120 mV, with current recordings taken
211 every 20 seconds. Once steady-state current values were achieved, cumulative drug application
212 was performed, starting with negative control (0.1% DMSO) followed by 1 μM PalGly.

213 **Whole-Cell Voltage-Clamp Recordings of TRPC5 Channels** 214 **in HEK293 Cells**

215 The HEK293T cells (China Infrastructure of Cell Line Resource) were grown in culture dishes for
216 24 h, and plasmids expressing hTRPC5 (NM_012471) were transfected into HEK293T cells using
217 lipofectamine 3000. The extracellular Solution (mM) contained: 145 NaCl, 4 KCl, 1 MgCl₂·6H₂O,
218 2 CaCl₂·2H₂O, 10 D-Glucose, 10 HEPES, adjusted to pH 7.4 with NaOH. The intracellular
219 Solution (mM) contained: 120 Cs-aspartic acid, 20 CsCl, 2 MgCl₂·6H₂O, 8.8 CaCl₂·2H₂O, 10
220 EGTA, 10 HEPES, 2 Na₂-ATP, adjusted to pH 7.2 with CsOH. Once a whole-cell seal is
221 established, the cell membrane potential is clamped at -80 mV. The voltage is stepped from 0 mV
222 to -100 mV and maintained for 1 ms, followed by a ramp to 100 mV for 300 ms, and then
223 repolarized to 0 mV for 50 ms. Data collection is repeated every 10 seconds to observe the effects
224 of the PalGly on the TRPC5 current.

225 **Whole-cell current recording for ventricular cardiomyocytes**

226 The extracellular Solution (mM) contained: 137 NaCl, 4 KCl, 10 HEPES, 10 D-Glucose, 1
227 MgCl₂·6H₂O, 2 CaCl₂·2H₂O, adjusted to pH 7.4 with NaOH. The intracellular Solution (mM)
228 contained: 135 KCl, 2 MgCl₂·6H₂O, 10 HEPES, 1 EGTA, 4 Mg-ATP, 0.3 NaGTP, adjusted to pH
229 7.2 with KOH. All the experiments were performed at a temperature of 23 ± 1 °C. For ventricular
230 cardiomyocytes, the cells are clamped at -80 mV, and the recording is switched to the current
231 clamp mode with I = 0. Ventricular myocytes require stimulation to generate action potentials. The
232 parameters for the inward current pulse stimulation are as follows: duration of 10 ms and
233 stimulation amplitude ranging from 0.1 to 1 nA.

234 **Measurements of Ca²⁺ sparks**

235 Isolated cardiomyocytes were subjected to a fluorescent calcium indicator, Fluo-4-AM
236 (Invitrogen), for 15 minutes at room temperature. Following this incubation period, the cells
237 underwent centrifugation, after which the supernatant was carefully removed. The cells were then
238 resuspended in fresh Tyrode solution containing 250 µmol/L probenecid sodium for an additional
239 20 minutes to facilitate the de-esterification of the dye and was carried out in laminin-coated
240 dishes. Cytosolic Ca²⁺ levels were monitored utilizing a confocal microscope (Leica SP8; Leica,
241 Wetzlar, Germany) operating in line-scan mode at a frequency of 700 Hz. Ca²⁺ sparks were
242 invoked after a 20-second field stimulation (1Hz, 4ms, 40V) with a stimulator (MyoPacer EP,
243 IONOPTIX). The subsequent detection and quantification of calcium sparks were performed by
244 SparkMaster 2³⁴.

245 **Lipidomic and transcriptomic analysis**

246 To extract cardiomyocytes, using ice-cold ethanol to anesthetize neonatal rats (0-3 days) followed
247 by cervical dislocation for euthanasia. Dissect immediately the chest cavity to remove the heart.
248 Place the heart in a petri dish containing cold PBS buffer. Cut the heart into small pieces and
249 isolate cardiomyocytes using a neonatal Cardiomyocyte Isolation Kit, rat (Miltenyi Biotec,
250 Germany) according to its protocol. After 1 hour of differential adherence, the suspending cells
251 were considered cardiomyocytes and were transferred to culture flasks containing DMEM
252 supplemented with 20% FBS for continued culture over 48 hours. Following this, the medium is
253 replaced with serum-free DMEM for 24 hours, after which 1 µM PalGly (dissolved in DMSO) or
254 an equivalent volume of DMSO is added for an additional 24-hour incubation. Subsequently, the

255 culture medium is extracted for lipidomic analysis, and RNA is extracted for RNA-seq
256 transcriptomic analysis. The RNA-seq data can be accessed in the GEO database (GSE278421).
257 We analyzed the altered lipid-related pathways by a lipid pathway enrichment analysis (LIPEA).
258 DEGs and GSEA were analyzed using clusterProfiler 4.10.1.

259 **Statistical analysis**

260 Data from the same cells or hearts before and after treatment are analyzed using a paired samples
261 t-test, while comparisons between different cell groups are conducted using an two-sided
262 independent samples t-test. The concentration-response curves were fitted to a four-parameter Hill
263 equation. All analyses were performed in R 4.3.2 and GraphPad Prism 10.2.3.

264 **Ethics**

265 The UKB participants gave informed written consent, and ethical approval was obtained from the
266 North West Centre for Research Ethics Committee. The deCode participants who donated samples
267 gave informed consent, and the National Bioethics Committee of Iceland approved the study. The
268 All GWAS human participants provided written informed consent, and all studies had received
269 approval from the appropriate ethical review boards.

270 **Results**

271 The flowchart of the MR design is presented in **Figure 1**. Instrument variables used in this study
272 are presented in **Table S2-5**.

273 **Circulating transcripts and proteins that causally associated** 274 **with the risk of BrS**

275 The overview of the results of MR and colocalization analysis is presented in **Figure 2**. A total of
276 nine proteins (H6PD, ANXA4, CXCL6, LRP11, CTSB, DEFB1, PDGFD, SPATA20, GSS) from
277 deCode genetics reached the Bonferroni corrected threshold ($p < 0.05/1320$) among which four
278 proteins (CXCL6, CTSB, SPATA20, DEFB1) were with high colocalization support ($PPH_4 > 0.8$)
279 (**Table 1**), while 13 proteins (CR1, CXCL6, NAAA, ARSB, HCG22, LTA, CTSB, IGFBP3,
280 EPHA1, ECHDC3, AAMDC, ZFYVE19, DCC) from UKB-PPP reached Bonferroni corrected
281 threshold ($p < 0.05/1590$) among which eight proteins (CR1, CXCL6, NAAA, LTA, IGFBP3,
282 EPHA1, AAMDC, DCC) were with high colocalization support. In addition, 12 genes at the
283 transcript level with high colocalization support from eQTLgen were significantly associated with
284 BrS (LUZP1, PCYOX1, NEIL2, MFHAS1, FAM86B3P, SCAND2P, C15orf26, ZSCAN2,
285 ADAMTS17, UBTF, DESI1, EP300). Detailed results are presented in **Table S6-9**. Enrichment
286 analysis showed that IGFBP3 and EPHA1 were significantly associated with fibronectin-binding
287 (GO:0001968) after FDR adjustments.

288 **3.2 Circulating protein levels affect genetically proxied ECG** 289 **morphology**

290 Despite the main ECG characteristics of BrS present in the right precordial leads, causal inference
291 of circulating proteins on three-lead exercise ECG morphology GWAS may unveil potential
292 mechanisms. For proteins that passed both MR and colocalization thresholds, top cis-pQTLs were
293 selected to represent the expression of the specific proteins (Figure S1). The AAMDC, CXCL6,

294 CTSB, and NAAA affected the slope of the ST segment, higher expression of CXCL6 increased
295 the risk of BrS while causing ST-segment elevation. The SPATA20 was associated with a shift of P
296 wave and PR interval, we postulate that this may be related to the cis-pQTL rs34081637 located at
297 the CACNA1G locus (adjacent downstream of SPATA20). The voltage-dependent calcium
298 channel, T-type, alpha 1G subunit (encoded by CACNA1G) is one of the components of the
299 calcium clock. Unfortunately, we were unable to identify any pQTLs or eQTLs for CACNA1G to
300 proxy its effects on ECG morphology or BrS.

301 **3.3 IGFBP3 increases the risk of BrS and is mediated by** 302 **N-palmitoyl glycine**

303 A total of 69 circulating metabolites were nominally significant, and only one metabolite
304 (N-palmitoyl glycine, PalGly) reached the Bonferroni corrected threshold ($p < 0.05/1190$) (**Table**
305 **S9**). Genetically proxied circulating PalGly significantly increased the risk of BrS (per SD, OR
306 1.42, 95% CI 1.20-1.67). Mediation analysis showed that one causally BrS-associated circulating
307 protein (IGFBP3) increased the risk of BrS partly via PalGly (Table 2).

308 **3.4 PalGly, IGFBP3, CR1, and DCC reduce the risks of** 309 **cardiometabolic diseases while CXCL6 increases the risks**

310 To determine potential therapeutic targets for BrS, we performed MR analyses of the genetically
311 proxied PalGly and proteins on 28 cardiometabolic traits. Surprisingly, PalGly reduced the risks of
312 AF and HF, which was in discordance with its effect on BrS (Table 3). The IGFBP3 showed
313 similar effects with the PalGly with reduced cardiometabolic ischemic stroke risk (Table 4). The
314 CXCL6 increased the risk of AF while CR1 and DCC reduced the risk of cardioembolic strokes

315 and HF respectively. The effects of the CXCL6, CR1, and DCC toward the cardiometabolic traits
316 were in concordance with their effects towards BrS, indicating these targets were therapeutic.
317 Detailed results of potential targets on cardiometabolic traits were presented in **Table S10**.

318 **3.5 PalGly may directly bind to BrS-associated proteins**

319 We performed molecular docking of the PalGly with target proteins. The max binding affinities
320 obtained were -5.4 kcal/mol for DCC, -5.8 kcal/mol for CR1, -5.9 kcal/mol for CTSS, -7.6
321 kcal/mol for NAAA, -5.8 kcal/mol for EPHA1, -5.7 kcal/mol for IGF1/IGFBP3/ALS complex,
322 and -6.3 kcal/mol for LTA, indicating that the PalGly has the moderate predicted interaction with
323 these targets (**Table S11**). Docking results also revealed that the PalGly forms three hydrogen
324 bonds and exhibits three hydrophobic interactions with DCC, forms three hydrogen bonds and
325 exhibits four hydrophobic interactions with CR1, forms two hydrogen bonds and exhibits seven
326 hydrophobic interactions with EPHA1, and forms one hydrogen bond and exhibits five
327 hydrophobic interactions with IGF1/IGFBP3/ALS complex, suggests stable binding
328 conformations.

329 **3.6 PalGly does not interact with Nav1.5 but increases** 330 **calcium sparks of ventricular cardiomyocytes**

331 Mutations in the SCN5A gene are the most known in BrS, therefore we first investigated whether
332 PalGly administration under maximum solubility (1 μ M) can affect peak sodium current ($I_{NaV1.5}$),
333 and results showed that the effect was not significant (**Figure 3A**). Next, because the PalGly can
334 induce calcium influx in neurons³⁵, we investigate its effect on calcium spark on rabbit primary
335 ventricular cardiomyocytes. After 1 μ M PalGly infusion and at least 20-second 1 Hz field

336 stimulations, the amplitude of calcium sparks was significantly increased (**Figure 3B**) with
337 increased width, duration, and frequency, while the time to peak of sparks was significantly
338 reduced.

339 **3.7 PalGly activates the hTRPC5 channel**

340 PalGly activates a TRP-like channel in dorsal root ganglia³⁵, and there is speculation that PalGly is
341 a direct transient receptor potential (TRP) channel 5 (TRPC5) agonist³⁶. Therefore, we performed
342 molecular docking that showed PalGly can bind both class 1 & 2 hTRPC5 channels. The docking
343 results for class 1 hTRPC5 (the dominant one) were presented in **Figure 4A**, the binding affinity
344 for class 2 hTRPC5 was -5.9 kcal/mol, and PalGly forms two hydrogen bonds in Chain A (Gln507,
345 Trp435) and exhibits five hydrophobic interactions (Chain A: Ile484, Leu491, Leu514; Chain D
346 Thr603, Thr607). Next, we expressed hTRPC5 in HEK293 cells to perform
347 whole-cell patch-clamp recording. The results demonstrated that PalGly significantly increased
348 both inward and outward currents of hTRPC5 at its maximum solubility (1 μ M), with the outward
349 current increasing by approximately two-fold and the inward current increasing by approximately
350 six-fold, and these currents can be diminished by the TRPC5 inhibitor ML204 (**Figure 4B**). Since
351 1 μ M reached the maximum solubility of PalGly, it was not possible to calculate the EC₅₀ value
352 for PalGly activating hTRPC5. Consequently, we calculated the EC₅₀ value for PalGly to be
353 approximately 104 nM (inward current) and 128.3 nM (outward current) by co-administering 20
354 μ M of the TRPC5 selective agonist rosiglitazone (**Figure 4C**).

355 **3.8 PalGly shortens action potential duration and QT** 356 **interval**

357 We subsequently investigated the effects of PalGly on isolated primary rabbit ventricular
358 myocytes and Langendorff-perfused hearts. After administering or perfusing 1 μ M PalGly for at
359 least 10 minutes, we observed a significant shortening in the action potential duration (APD) of
360 both cardiomyocytes (**Figure 5A**) and the overall heart, as well as a significant shortening of the
361 QT interval (**Figure 5B**). Notably, the influence of PalGly appeared to be more pronounced on
362 early repolarization, as indicated by a greater difference in APD30/MAPD30 compared to
363 APD90/MAPD90. Given that rosiglitazone can suppress several cardiac transmembrane ion
364 currents³⁷, we did not use it as a TRPC5 positive control. We further assessed the impact of PalGly
365 on QTc through MR analysis, confirming a causal relationship between PalGly and a shortened
366 QTc interval (per SD, β -0.54, 95% CI -1.01, -0.07, $p = 0.03$).

367 **3.9 PalGly alters the transcriptomic and lipidomic profile of** 368 **cardiomyocytes**

369 We added a concentration of 3000 ng/ml of PalGly to the culture medium of primary neonatal rat
370 cardiomyocytes for 24 hours. Mass spectrometry quantification of the culture medium revealed
371 that the PalGly concentration decreased to 20.18 ± 16.68 ng/ml, while in the medium of normally
372 cultured cardiomyocytes, the PalGly concentration was approximately 0.24 ± 0.16 ng/ml. Next,
373 following administration with 1 μ M PalGly for 24 hours, we extracted the culture medium to
374 perform non-targeted lipidomic analysis, and RNA for RNA-seq and subsequent transcriptomic
375 analysis. Five lipid species were significantly reduced (LPC 18:1, PA 33:1; PA 16:0-17:1, CL 68:3;

376 CL 34:1-34:2, FA 19:1, and PC 32:4e;), while 15 lipid species were significantly increased (FA
377 20:2, FA 22:3, PG 34:0; PG 16:0-18:0, PE 36:1, FA 18:1, FA 18:2, LPE 16:1e, LPE 18:2e, PI 40:5;
378 PI 18:0-22:5, PI 38:5; PI 18:1-20:4, SM d44:3, PS 40:6, PE 40:5; PE 18:0-22:5, PE 40:4, and TAG
379 58:5e; TAG 18:0e-18:1-22:4) (**Figure 6A**). Enrichment analysis indicated that these lipid
380 alterations were associated with glycerophospholipid metabolism, ferroptosis, and autophagy
381 (**Figure 6B**). The differential expression genes (DEGs) from RNA-seq are presented in **Figure 6C**.
382 Gene Ontology (GO) and KEGG enrichment revealed that PalGly not only induces changes in
383 autophagy-related genes but is also associated with alterations in various pathways, including
384 ubiquitin-related pathways, MAPK, and TNF signalling (**Figure 6D**). Additionally, Gene Set
385 Enrichment Analysis (GSEA) indicated that PalGly negatively regulates the innate immune
386 response (**Figure 6E**).

387 **4.0 Discussion**

388 Through conducting MR and colocalization analysis involving over 4000 proteins and 1000
389 metabolites, we have identified several previously unreported potential BrS targets as well as
390 discovered the similarities and differences of these targets' effects on BrS and other
391 cardiometabolic disorders. Our MR analysis and colocalization analysis using eQTLs showed
392 minimal overlap compared to the results by pQTLs. Given that proteins are regarded as primary
393 function executors, we focused on investigating the proteome/metabolome-wide results.
394 Combining the MR and colocalization results, we found that genetically predicted CXCL6
395 increased the risks of BrS and AF, and CR1 and DCC reduced the risks of BrS, leading to lower
396 risks of cardioembolic stroke and HF respectively. PalGly and IGFBP3, on the other hand,

397 increased the risk of BrS while reducing the risks of cardiometabolic diseases. Interestingly,
398 molecular docking analysis revealed that PalGly not only has the potential to influence BrS risk
399 itself but can also interact with BrS-related proteins (DCC, CR1, CTSB, NAAA, DEFB1, EPHA1,
400 IGF1/IGFBP3/ALS, and LTA). Although mediation analysis indicated that only IGFBP3 exhibited
401 a significant mediating effect. Furthermore, we identified for the first time that PalGly can
402 enhance myocardial calcium sparks and shorten action potential duration (APD) and QT interval,
403 with these electrophysiological effects likely mediated by the activation of TRPC5.

404 Although traditionally considered as a pure electrical disorder without structural alteration,
405 there is accumulating evidence suggesting that myocarditis and inflammation infiltration may
406 contribute to BrS pathogenesis³⁸, and C-reactive protein (CRP) was found to be an independent
407 marker for symptomatic BrS³⁹. Myocardial inflammation was detected in two patients with BrS
408 and arrhythmic storm by fluorodeoxyglucose–positron-emission tomography (FDG-PET)⁴⁰. One
409 patient remained free of ICD shocks for 1 year after immunosuppression therapy. However, these
410 studies were either cases or cross-sectional investigations, lacking robust and causal evidence. The
411 CXCL6, CR1, and DCC screened by our analyses are proteins associated with immune response.
412 CXCL6 primarily exerts pro-inflammatory effects by recruiting neutrophils⁴¹ and acts as a
413 pro-angiogenic and pro-fibrotic paracrine factor secreted by endothelial cells and cardiac
414 progenitor-like cells^{41,42}. Elevated levels of CXCL6 are associated with higher idiopathic
415 pulmonary fibrosis mortality⁴³. CR1, on the other hand, exerts anti-inflammatory effects by
416 facilitating the clearance of immune complexes and inhibits both C3 and C5 convertase activity⁴⁴.
417 Interestingly, administration of a recombinant form of soluble CR1 (TP10/CDX-1135) led to a
418 decreased incidence of cardiovascular events in specifically male individuals undergoing cardiac

419 surgery on cardiopulmonary bypass⁴⁵. Gender difference is a well-recognized pattern of BrS,
420 female patients with BrS are much rarer⁴⁶, and the cohort included in this study is predominantly
421 comprised of male participants (74%), suggesting inflammation may contribute to the gender
422 difference of BrS. DCC is a netrin-1 receptor that is also involved in inflammation and
423 angiogenesis and exerts its cardioprotective effect via Nitric oxide (NO) sustaining⁴⁷. In-vitro
424 evidence suggests that the cardioprotective effects exerted by netrin-1 in ischemia-reperfusion
425 injury are by DCC-dependent endothelial-derived and cardiomyocyte-derived NO. Taken together,
426 the immune/inflammation response is likely involved in the pathogenesis of BrS, and
427 pharmacotherapies targeting these targets may hold promise as potential interventions.

428 Lipidomic and transcriptomic analyses indicated that PalGly negatively regulates the innate
429 immune response, a finding that parallels the effects of TRPC5. PalGly is one of the fatty acid
430 amides that serves as an endogenous signalling molecule⁴⁸. It presents around 250-fold greater
431 amounts in the skin (1612 pmol/g) compared to the amounts in the heart (6 pmol/g)³⁵. Under the
432 concentration of 27 μ M, it potently inhibits heat-evoked firing of nociceptive neurons in rat dorsal
433 horn and induced transient calcium influx in adult rat dorsal root ganglion (DRG) cells and a
434 DRG-like cell line (F-11)³⁵. Our results demonstrate that PalGly significantly increased the
435 calcium spark amplitude in adult rabbit ventricular cardiomyocytes under field stimulation.
436 Additionally, it augmented the width, duration, and frequency of calcium sparks while decreasing
437 the time to peak. PalGly also significantly shortened APD both in vivo and ex vivo and shortened
438 QT interval. We identified PalGly as an endogenous TRPC5 activator through patch-clamp
439 experiments, the agonizing effect can be abolished by the TRPC5 inhibitor ML204. TRPCs
440 contribute to Ca²⁺ signalling and changes in cell excitability. TRPC5 channels, like PalGly, are

441 predominantly expressed in the brain⁴⁹ and exist in a homomeric form or as a heteromer combined
442 with TRPC1/TRPC4/TRPC5⁵⁰. TRPC5 is a member of the TRP channel family, reportedly
443 involved in cardiovascular pathophysiology⁵¹. Rosiglitazone, as a TRPC5 agonist, attenuates atrial
444 structural remodelling and atrial fibrillation⁵², which is consistent with our findings that PalGly
445 reduces the risk of AF. However, the underlying mechanism by which PalGly significantly
446 shortens action potential duration (APD), and QT interval and ultimately increases the risk of BrS
447 remains unclear. TRPC5 homomers and heteromers display distinct current-voltage (I-V)
448 relationships. TRPC5 homomer or TRPC5/TRPC4 heteromer shows a doubly rectifying I-V curve
449 characterized by substantial inward currents. In contrast, the TRPC5/TRPC1 heteromer exhibits
450 predominantly outward rectification, manifesting relatively minor inward currents at negative
451 potentials⁵³. This distinct rectification behaviour may contribute to the changes observed in action
452 potentials. Additionally, the intracellular calcium increase induced by TRPC5 activation can
453 enhance the activity of calcium-dependent potassium channels (i.e. small conductance
454 calcium-activated potassium channels, SK channels), promoting faster repolarization. PalGly may
455 even directly activate relevant repolarization channels, contributing to these effects.

456 In addition, It was reported that IGFBP3 is significantly associated with higher sudden
457 cardiac arrest (SCA) and syncope in the SCN5A mutation– BrS patients⁵⁴ and higher serum
458 calcium⁵⁵. Our results showed that genetically predicted circulating IGFBP3 is associated with a
459 higher risk of BrS, and the effect is partly mediated by the PalGly.

460 As BrS is relatively rare, we were unable to replicate our current findings through other
461 cohorts. The cohorts available to us consisted of individuals of European ancestry, which may
462 limit the generalizability of our results, particularly considering the higher prevalence of BrS in

463 Southeast Asia⁵⁶. We also were unable to perform sex-stratified and mutation-stratified analyses
464 due to a lack of available summary-level statistics.

465 Collectively, our study underscores the involvement of PalGly, TRPC5, and
466 inflammation-related proteins in the pathophysiology of BrS.

467 **Funding**

468 This work was funded by the Chinese National Natural Science Foundation (Grant No. 81930105
469 and 82370312).

470 **Acknowledgements**

471 L.W. is supported by the National Natural Science Foundation of China (No. 82370312 and
472 81930105). This work was supported by High-performance Computing Platform of Peking
473 University. The funders had no role in the study design, data collection and analysis, decision to
474 publish, or preparation of the manuscript. The authors thank members of all contributing studies
475 for sharing their summary-level GWAS data.

476 **Conflict of interests**

477 None declared.

478 **Reference**

479 1 Brugada, P. & Brugada, J. Right bundle branch block, persistent ST segment
480 elevation and sudden cardiac death: a distinct clinical and electrocardiographic
481 syndrome. A multicenter report. *J Am Coll Cardiol* **20**, 1391-1396 (1992).

- 482 [https://doi.org/10.1016/0735-1097\(92\)90253-j](https://doi.org/10.1016/0735-1097(92)90253-j)
- 483 2 Monasky, M. M. *et al.* Genotype-Phenotype Correlation in a Family with Brugada
484 Syndrome Harboring the Novel p.Gln371* Nonsense Variant in the SCN5A Gene. *Int J*
485 *Mol Sci* **20** (2019). <https://doi.org/10.3390/ijms20225522>
- 486 3 Milman, A. *et al.* Profile of patients with Brugada syndrome presenting with their first
487 documented arrhythmic event: Data from the Survey on Arrhythmic Events in
488 BRUGADA Syndrome (SABRUS). *Heart Rhythm* **15**, 716-724 (2018).
489 <https://doi.org/10.1016/j.hrthm.2018.01.014>
- 490 4 Barc, J. *et al.* Genome-wide association analyses identify new Brugada syndrome risk
491 loci and highlight a new mechanism of sodium channel regulation in disease
492 susceptibility. *Nat Genet* **54**, 232-239 (2022).
493 <https://doi.org/10.1038/s41588-021-01007-6>
- 494 5 Priori, S. G. *et al.* Executive summary: HRS/EHRA/APHRS expert consensus
495 statement on the diagnosis and management of patients with inherited primary
496 arrhythmia syndromes. *Europace* **15**, 1389-1406 (2013).
497 <https://doi.org/10.1093/europace/eut272>
- 498 6 Priori, S. G. *et al.* 2015 ESC Guidelines for the management of patients with
499 ventricular arrhythmias and the prevention of sudden cardiac death: The Task Force
500 for the Management of Patients with Ventricular Arrhythmias and the Prevention of
501 Sudden Cardiac Death of the European Society of Cardiology (ESC). Endorsed by:
502 Association for European Paediatric and Congenital Cardiology (AEPC). *Eur Heart J*
503 **36**, 2793-2867 (2015). <https://doi.org/10.1093/eurheartj/ehv316>

- 504 7 Al-Khatib, S. M. *et al.* 2017 AHA/ACC/HRS Guideline for Management of Patients
505 With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death: Executive
506 Summary: A Report of the American College of Cardiology/American Heart
507 Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society.
508 *Circulation* **138**, e210-e271 (2018). <https://doi.org/10.1161/cir.0000000000000548>
- 509 8 Verweij, N. *et al.* The Genetic Makeup of the Electrocardiogram. *Cell Syst* **11**,
510 229-238.e225 (2020). <https://doi.org/10.1016/j.cels.2020.08.005>
- 511 9 Nauffal, V. *et al.* Monogenic and Polygenic Contributions to QTc Prolongation in the
512 Population. *Circulation* **145**, 1524-1533 (2022).
513 <https://doi.org/10.1161/circulationaha.121.057261>
- 514 10 Ferkingstad, E. *et al.* Large-scale integration of the plasma proteome with genetics
515 and disease. *Nat Genet* **53**, 1712-1721 (2021).
516 <https://doi.org/10.1038/s41588-021-00978-w>
- 517 11 Sun, B. B. *et al.* Plasma proteomic associations with genetics and health in the UK
518 Biobank. *Nature* **622**, 329-338 (2023). <https://doi.org/10.1038/s41586-023-06592-6>
- 519 12 Vösa, U. *et al.* Large-scale cis- and trans-eQTL analyses identify thousands of genetic
520 loci and polygenic scores that regulate blood gene expression. *Nature Genetics* **53**,
521 1300-1310 (2021). <https://doi.org/10.1038/s41588-021-00913-z>
- 522 13 Chen, Y. *et al.* Genomic atlas of the plasma metabolome prioritizes metabolites
523 implicated in human diseases. *Nature Genetics* **55**, 44-53 (2023).
524 <https://doi.org/10.1038/s41588-022-01270-1>
- 525 14 Willer, C. J. *et al.* Discovery and refinement of loci associated with lipid levels. *Nat*

- 526 *Genet* **45**, 1274-1283 (2013). <https://doi.org/10.1038/ng.2797>
- 527 15 Barton, A. R., Sherman, M. A., Mukamel, R. E. & Loh, P.-R. Whole-exome imputation
528 within UK Biobank powers rare coding variant association and fine-mapping analyses.
529 *Nature Genetics* **53**, 1260-1269 (2021). <https://doi.org/10.1038/s41588-021-00892-1>
- 530 16 Evangelou, E. *et al.* Genetic analysis of over 1 million people identifies 535 new loci
531 associated with blood pressure traits. *Nat Genet* **50**, 1412-1425 (2018).
532 <https://doi.org/10.1038/s41588-018-0205-x>
- 533 17 Chen, J. *et al.* The trans-ancestral genomic architecture of glycemic traits. *Nat Genet*
534 **53**, 840-860 (2021). <https://doi.org/10.1038/s41588-021-00852-9>
- 535 18 Soranzo, N. *et al.* Common variants at 10 genomic loci influence hemoglobin A_{1c}(C)
536 levels via glycemic and nonglycemic pathways. *Diabetes* **59**, 3229-3239 (2010).
537 <https://doi.org/10.2337/db10-0502>
- 538 19 Yengo, L. *et al.* Meta-analysis of genome-wide association studies for height and body
539 mass index in ~700000 individuals of European ancestry. *Hum Mol Genet* **27**,
540 3641-3649 (2018). <https://doi.org/10.1093/hmg/ddy271>
- 541 20 Malik, R. *et al.* Multiancestry genome-wide association study of 520,000 subjects
542 identifies 32 loci associated with stroke and stroke subtypes. *Nat Genet* **50**, 524-537
543 (2018). <https://doi.org/10.1038/s41588-018-0058-3>
- 544 21 Nikpay, M. *et al.* A comprehensive 1,000 Genomes-based genome-wide association
545 meta-analysis of coronary artery disease. *Nat Genet* **47**, 1121-1130 (2015).
546 <https://doi.org/10.1038/ng.3396>
- 547 22 Shah, S. *et al.* Genome-wide association and Mendelian randomisation analysis

- 548 provide insights into the pathogenesis of heart failure. *Nat Commun* **11**, 163 (2020).
549 <https://doi.org/10.1038/s41467-019-13690-5>
- 550 23 Kurki, M. I. *et al.* FinnGen provides genetic insights from a well-phenotyped isolated
551 population. *Nature* **613**, 508-518 (2023). <https://doi.org/10.1038/s41586-022-05473-8>
- 552 24 Pattaro, C. *et al.* Genetic associations at 53 loci highlight cell types and biological
553 pathways relevant for kidney function. *Nat Commun* **7**, 10023 (2016).
554 <https://doi.org/10.1038/ncomms10023>
- 555 25 Forgetta, V. *et al.* Rare Genetic Variants of Large Effect Influence Risk of Type 1
556 Diabetes. *Diabetes* **69**, 784-795 (2020). <https://doi.org/10.2337/db19-0831>
- 557 26 Xue, A. *et al.* Genome-wide association analyses identify 143 risk variants and
558 putative regulatory mechanisms for type 2 diabetes. *Nat Commun* **9**, 2941 (2018).
559 <https://doi.org/10.1038/s41467-018-04951-w>
- 560 27 Purcell, S. *et al.* PLINK: a tool set for whole-genome association and population-based
561 linkage analyses. *Am J Hum Genet* **81**, 559-575 (2007).
562 <https://doi.org/10.1086/519795>
- 563 28 Hemani, G., Tilling, K. & Davey Smith, G. Orienting the causal relationship between
564 imprecisely measured traits using GWAS summary data. *PLoS Genet* **13**, e1007081
565 (2017). <https://doi.org/10.1371/journal.pgen.1007081>
- 566 29 Skrivankova, V. W. *et al.* Strengthening the Reporting of Observational Studies in
567 Epidemiology Using Mendelian Randomization: The STROBE-MR Statement. *Jama*
568 **326**, 1614-1621 (2021). <https://doi.org/10.1001/jama.2021.18236>
- 569 30 Giambartolomei, C. *et al.* Bayesian test for colocalisation between pairs of genetic

- 570 association studies using summary statistics. *PLoS Genet* **10**, e1004383 (2014).
571 <https://doi.org/10.1371/journal.pgen.1004383>
- 572 31 Tofighi, D. & MacKinnon, D. P. RMediation: An R package for mediation analysis
573 confidence intervals. *Behavior Research Methods* **43**, 692-700 (2011).
574 <https://doi.org/10.3758/s13428-011-0076-x>
- 575 32 Du, L. *et al.* Dockey: a modern integrated tool for large-scale molecular docking and
576 virtual screening. *Brief Bioinform* **24** (2023). <https://doi.org/10.1093/bib/bbad047>
- 577 33 Zhang, Q. *et al.* Increase in CO(2) levels by upregulating late sodium current is
578 proarrhythmic in the heart. *Heart Rhythm* **16**, 1098-1106 (2019).
579 <https://doi.org/10.1016/j.hrthm.2019.01.029>
- 580 34 Tomek, J., Nieves-Cintron, M., Navedo, M. F., Ko, C. Y. & Bers, D. M. SparkMaster 2:
581 A New Software for Automatic Analysis of Calcium Spark Data. *Circ Res* **133**, 450-462
582 (2023). <https://doi.org/10.1161/circresaha.123.322847>
- 583 35 Rimmerman, N. *et al.* N-palmitoyl glycine, a novel endogenous lipid that acts as a
584 modulator of calcium influx and nitric oxide production in sensory neurons. *Mol*
585 *Pharmacol* **74**, 213-224 (2008). <https://doi.org/10.1124/mol.108.045997>
- 586 36 Bradshaw, H. B., Raboune, S. & Hollis, J. L. Opportunistic activation of TRP receptors
587 by endogenous lipids: exploiting lipidomics to understand TRP receptor cellular
588 communication. *Life Sci* **92**, 404-409 (2013). <https://doi.org/10.1016/j.lfs.2012.11.008>
- 589 37 Szentandrassy, N. *et al.* Effects of rosiglitazone on the configuration of action
590 potentials and ion currents in canine ventricular cells. *Br J Pharmacol* **163**, 499-509
591 (2011). <https://doi.org/10.1111/j.1476-5381.2011.01215.x>

- 592 38 Pieroni, M. *et al.* Electroanatomic and Pathologic Right Ventricular Outflow Tract
593 Abnormalities in Patients With Brugada Syndrome. *Journal of the American College of*
594 *Cardiology* **72**, 2747-2757 (2018).
595 <https://doi.org/https://doi.org/10.1016/j.jacc.2018.09.037>
- 596 39 Bonny, A. *et al.* C-reactive protein levels in the brugada syndrome. *Cardiol Res Pract*
597 **2011**, 341521 (2011). <https://doi.org/10.4061/2011/341521>
- 598 40 Li, A., Tung, R., Shivkumar, K. & Bradfield, J. S. Brugada syndrome-Malignant
599 phenotype associated with acute cardiac inflammation? *HeartRhythm Case Rep* **3**,
600 384-388 (2017). <https://doi.org/10.1016/j.hrcr.2017.04.011>
- 601 41 Gijbbers, K. *et al.* GCP-2/CXCL6 synergizes with other endothelial cell-derived
602 chemokines in neutrophil mobilization and is associated with angiogenesis in
603 gastrointestinal tumors. *Exp Cell Res* **303**, 331-342 (2005).
604 <https://doi.org/10.1016/j.yexcr.2004.09.027>
- 605 42 Torán, J. L. *et al.* CXCL6 is an important paracrine factor in the pro-angiogenic human
606 cardiac progenitor-like cell secretome. *Sci Rep* **7**, 12490 (2017).
607 <https://doi.org/10.1038/s41598-017-11976-6>
- 608 43 Bahudhanapati, H. *et al.* Increased expression of CXCL6 in secretory cells drives
609 fibroblast collagen synthesis and is associated with increased mortality in idiopathic
610 pulmonary fibrosis. *Eur Respir J* **63** (2024).
611 <https://doi.org/10.1183/13993003.00088-2023>
- 612 44 Shandelya, S. M., Kuppusamy, P., Herskowitz, A., Weisfeldt, M. L. & Zweier, J. L.
613 Soluble complement receptor type 1 inhibits the complement pathway and prevents

- 614 contractile failure in the postischemic heart. Evidence that complement activation is
615 required for neutrophil-mediated reperfusion injury. *Circulation* **88**, 2812-2826 (1993).
616 <https://doi.org/10.1161/01.cir.88.6.2812>
- 617 45 Lazar, H. L. *et al.* Beneficial Effects of Complement Inhibition With Soluble
618 Complement Receptor 1 (TP10) During Cardiac Surgery. *Circulation* **116**, I-83-I-88
619 (2007). <https://doi.org/doi:10.1161/CIRCULATIONAHA.106.677914>
- 620 46 Milman, A. *et al.* Gender differences in patients with Brugada syndrome and
621 arrhythmic events: Data from a survey on arrhythmic events in 678 patients. *Heart*
622 *Rhythm* **15**, 1457-1465 (2018). <https://doi.org/10.1016/j.hrthm.2018.06.019>
- 623 47 Li, Q., Wang, P., Ye, K. & Cai, H. Central role of SIAH inhibition in DCC-dependent
624 cardioprotection provoked by netrin-1/NO. *Proc Natl Acad Sci U S A* **112**, 899-904
625 (2015). <https://doi.org/10.1073/pnas.1420695112>
- 626 48 Ezzili, C., Otrubova, K. & Boger, D. L. Fatty acid amide signaling molecules. *Bioorg*
627 *Med Chem Lett* **20**, 5959-5968 (2010). <https://doi.org/10.1016/j.bmcl.2010.08.048>
- 628 49 Riccio, A. *et al.* mRNA distribution analysis of human TRPC family in CNS and
629 peripheral tissues. *Brain Res Mol Brain Res* **109**, 95-104 (2002).
630 [https://doi.org/10.1016/s0169-328x\(02\)00527-2](https://doi.org/10.1016/s0169-328x(02)00527-2)
- 631 50 Bröker-Lai, J. *et al.* Heteromeric channels formed by TRPC1, TRPC4 and TRPC5
632 define hippocampal synaptic transmission and working memory. *Embo j* **36**,
633 2770-2789 (2017). <https://doi.org/10.15252/emboj.201696369>
- 634 51 Du, S. L., Jia, Z. Q., Zhong, J. C. & Wang, L. F. TRPC5 in cardiovascular diseases.
635 *Rev Cardiovasc Med* **22**, 127-135 (2021). <https://doi.org/10.31083/j.rcm.2021.01.212>

- 636 52 Liu, T., Zhao, H., Li, J., Korantzopoulos, P. & Li, G. Rosiglitazone attenuates atrial
637 structural remodeling and atrial fibrillation promotion in alloxan-induced diabetic
638 rabbits. *Cardiovasc Ther* **32**, 178-183 (2014).
639 <https://doi.org/10.1111/1755-5922.12079>
- 640 53 Clapham, D. E. TRP channels as cellular sensors. *Nature* **426**, 517-524 (2003).
641 <https://doi.org/10.1038/nature02196>
- 642 54 Juang, J.-M. J. *et al.* Validation and Disease Risk Assessment of Previously Reported
643 Genome-Wide Genetic Variants Associated With Brugada Syndrome. *Circulation:
644 Genomic and Precision Medicine* **13**, e002797 (2020).
645 <https://doi.org/doi:10.1161/CIRCGEN.119.002797>
- 646 55 Van Hemelrijck, M., Shanmugalingam, T., Bosco, C., Wulaningsih, W. & Rohrmann, S.
647 The association between circulating IGF1, IGFBP3, and calcium: results from
648 NHANES III. *Endocr Connect* **4**, 187-195 (2015). <https://doi.org/10.1530/ec-15-0039>
- 649 56 Vutthikraivit, W. *et al.* Worldwide Prevalence of Brugada Syndrome: A Systematic
650 Review and Meta-Analysis. *Acta Cardiol Sin* **34**, 267-277 (2018).
651 [https://doi.org/10.6515/acs.201805_34\(3\).20180302b](https://doi.org/10.6515/acs.201805_34(3).20180302b)

652

653 **Author contribution**

- 654 Conceptualization, H.X.; methodology, H.X., B.L.; software, formal analysis, and investigation,
655 H.X.; electrophysiology experiments, H.X., B.L., and Y.C.; validation, H.X., B.L.; writing –
656 original draft, H.X.; writing – review & editing, B.L., L.Y., A.Z., and L.W.; visualization, H.X.,

657 B.L.; funding acquisition, L.W.; supervision, L.W.

658 **Data availability**

659 eQTLs: www.eqtlgen.org; deCode pQTLs: www.decode.com/summarydata/; UKB-PPP pQTLs:
660 ukb-ppp.gwas.eu; MetabolitesQTLs: www.ebi.ac.uk/gwas/studies/GCST90199637; Brugada
661 syndrome: www.ebi.ac.uk/gwas/studies/GCST90086158; ECGwas: <http://www.ecgenetics.org>;
662 QTc interval: https://personal.broadinstitute.org/ryank/Nauffal_2022_QT_GWAS_SAIGE.zip;
663 RNA-seq generated in this manuscript: GEO database under the code GSE278421.

664 **Code availability**

665 Code for MR can be accessed at github.com/HongxuanXu/Multiomics-brugada-mr.

666 **Abbreviations**

667 BrS: Brugada syndrome

668 ICD: implantable cardioverter-defibrillator

669 MR: mendelian randomization

670 ECG: electrocardiogram

671 GWAS: genome-wide association studies

672 QTL: quantitative trait loci

673 PBMC: peripheral blood mononuclear cell

674 IVW: Inverse variance weighted

675 ApoA1: apolipoprotein A1

676 ApoB: apolipoprotein B

677 HDL-C: high-density lipoprotein cholesterol

678 LDL-C: low-density lipoprotein cholesterol

- 679 Lp(a): Lipoprotein A
- 680 SBP: systolic blood pressure
- 681 DBP: diastolic blood pressure
- 682 HbA1c: Hemoglobin A1C
- 683 BMI: body mass index
- 684 AF: atrial fibrillation
- 685 CHD: coronary heart disease
- 686 HF: heart failure
- 687 PalGly: N-palmitoylglycine
- 688 APD: action potential duration
- 689 FDG-PET: fluorodeoxyglucose–positron-emission tomography
- 690 NO: Nitric oxide
- 691 DRG: dorsal root ganglion
- 692 DAD: delayed afterdepolarizations
- 693 SCA: sudden cardiac arrest
- 694

695 Table 1. Mendelian randomization analysis and colocalization of circulating proteins and
696 transcripts on Brugada syndorme

Data source	Exposure	Inverse variance weighted		Colocalization	
		OR per SD (95% CI)	P value	Analysis PPH ₄	
deCode	CXCL6	1.26 (1.16-1.36)	3.94E-08	1	
	CTSB	0.78 (0.71-0.86)	1.65E-06	1	
	DEFB1	1.26 (1.13-1.41)	2.78E-05	1	
	SPATA20	0.73 (0.64-0.85)	2.03E-05	1	
UKB-PPP	CXCL6	1.35 (1.22-1.49)	1.39E-08	1	
	CR1	0.80 (0.73-0.87)	1.65E-07	1	
	NAAA	0.87 (0.81-0.93)	1.54E-05	1	
	AAMDC	1.17 (1.09-1.25)	4.32E-06	0.81	
	DCC	0.66 (0.55-0.78)	1.46E-06	0.91	
	EPHA1	0.67 (0.56-0.79)	4.56E-06	1	
	IGFBP3	1.22 (1.12-1.33)	3.59E-06	1	
	LTA	0.88 (0.83-0.92)	1.56E-06	1	
	eQTLgen	LUZP1	0.58 (0.48-0.72)	2.66E-07	1
		PCYOX1	2.37 (1.70-3.30)	3.53E-07	1
NEIL2		1.51 (1.39-1.65)	1.74E-20	1	
MFHAS1		1.66 (1.44-1.91)	3.01E-12	1	
FAM86B3P		0.40 (0.29-0.55)	1.26E-08	0.95	

SCAND2P	0.61 (0.52-0.71)	6.29E-10	1
C15orf26	1.73 (1.43-2.10)	2.57E-08	0.93
ZSCAN2	0.35 (0.23-0.53)	6.93E-07	0.83
ADAMTS17	0.60 (0.50-0.74)	5.84E-07	0.96
UBTF	3.35 (2.05-5.46)	1.26E-06	0.98
DESI1	0.53 (0.42-0.67)	3.62E-08	0.85
EP300	0.62 (0.52-0.74)	1.48E-07	0.95

697

698

699 Table 2. The mediation effect of PalGly affects BrS

Protein	Total effect	Direct effect	Direct effect	Mediation	p	Mediation
		A	B	effect		proportion
		β (95% CI)	β (95% CI)	β (95% CI)		
IGFBP3	0.20 (0.12 to 0.28)	0.09 (0.05 to 0.12)	0.35 (0.18 to 0.51)	0.03 (0.01 to 0.04)	2.25e-06	3.05 (0.00 to 24.91)

700 ‘Total effect’ indicates the effect of the circulating proteins on BrS, ‘Direct effect A’ indicates the

701 effect of the circulating proteins on PalGly, ‘Direct effect B’ indicates the effect of PalGly on BrS,

702 ‘Mediation effect’ indicates the effect of the circulating proteins on BrS through PalGly. Total

703 effect, direct effect A and direct effect B were derived by IVW; mediation effect was derived by

704 Delta method.

705

706 Table 3. Mendelian randomization analysis of PalGly, IGFBP3 CXCL6, CR1, and DCC on
707 cardiometabolic diseases

Exposure	Cardiom etabolic trait	Inverse variance weighted		Weighted median	
		OR per SD (95% CI)	p	OR per SD (95% CI)	p
PalGly	AF	0.97 (0.94-0.99)	0.005	0.96 (0.93-1.00)	0.03
	HF	0.96 (0.93-0.99)	0.01	0.96 (0.92-1.00)	0.04
IGFBP3	AF	0.94 (0.92-0.96)	4.21E-11	0.96 (0.93-0.98)	6.61E-04
	Stroke	0.96 (0.94-0.99)	0.002	0.95 (0.91-0.98)	0.006
	Ischemi c stroke (cardioe mbolic)	0.91 (0.87-0.96)	3.91E-04	0.93 (0.86-0.99)	0.03
	Ischemi c stroke (large artery atherosc lerosis)	0.91 (0.85-0.97)	0.004	0.89 (0.81-0.97)	0.01
CXCL6	AF	1.03 (1.01-1.05)	0.003	1.04 (1.01-1.06)	0.01

CR1	Ischemic stroke (cardioembolic)	0.92 (0.88-0.97)	0.002	0.93 (0.86-1.00)	0.04
DCC	HF	0.91 (0.87-0.95)	2.37E-05	0.92 (0.86-0.98)	0.007

708

709 Table 4. Mendelian randomization analysis of PalGly, IGFBP3, CXCL6, and CR1 on

710 cardiometabolic factors


Exposure	Cardiometabolic factor	Inverse variance weighted			Weighted median		
		β per SD (95% CI)	p		β per SD (95% CI)	p	
PalGly	HDL-C	-0.06 (-0.11 to 0.04)	0.00		-0.05 (-0.10 to 0.03)	0.00	
	IGFBP3	SBP	-0.60 (-0.70 to -0.49)	2.07E-27		-0.65 (-0.79 to -0.50)	8.47E-18
	DBP	0.24 (0.17 to 0.31)	4.36E-12		0.24 (0.16 to 0.32)	2.73E-09	
	Two-hour glucose challenge	0.11 (0.03 to 0.20)	0.01		0.08 (0.01 to 0.15)	0.03	

	e					
	Waist	-0.03	(-0.05 to 2.67E-04	-0.03	(-0.05 to 0.004	
	circumf	-0.02)		-0.01)		
	erence					
	Waist-to	-0.02	(-0.03 to 0.01	-0.02	(-0.04 to 0.03	
	-hip	-0.01)		-0.00)		
	ratio					
CXCL6	HbA1C	-0.03	(-0.04 to 3.34E-05	-0.02	(-0.03 to 0.002	
		-0.01)		-0.01)		
	Waist-to	0.02	(0.00 to 0.03	0.02	(0.00 to 0.03	
	-hip	0.04)		0.04)		
	ratio					
CR1	Total	0.08	(0.02 to 0.08	0.07	(0.00 to 0.04	
	choleste	0.13)		0.14)		
	rol					

711


712

713



714

715 Figure 1. Flowchart of the MR design




716

717 Figure 2. Manhattan plot of significant proteins and transcripts. Red symbols indicate high

718 colocalization support. (A) Proteins from deCode. (B) Proteins from UKB-PPP. (C) Transcripts

719 from eQTLgen.



720

721 Figure 3. Sodium current and calcium spark traits induced by the palmitoylglycine.

722 (A) Left: representative peak sodium current ($\text{Na}_v1.5$) before and after the PalGly administration

723 in resting state or half inactivation state. The maximum solubility of palmitoylglycine in

724 extracellular fluid is around 1 μM . Right: normalized current before and after PalGly ($n = 5$,

725 paired t-test). (B) Left top: representative image of calcium in primary ventricular cardiomyocytes


726 dyed by Fluo4, AM. Left bottom: representative image (standard deviation transformed) of

727 calcium sparks after 20-second 1 Hz filed stimulations. Right: Delta F/F0 representing the

728 amplitude of calcium sparks is significantly higher after PalGly administration ($n_{\text{Control}} = 11$,

729 $n_{\text{PalGly}} = 38$ from 5 rabbits, unpaired t-test), each dot represents a mean value of calcium sparks

730 of one line-scanned ventricular cardiomyocyte. PalGly: palmitoylglycine.



731

732 Figure 4. PalGly binds to and agonizes the hTRPC5 channel

733 (A) molecular docking result for PalGly and class 1 hTRPC5. Chain C of hTRPC5 is in cyan,

734 PalGly is in orange, and hydrogen bonds are in magentas. The binding affinity is -5.9 kcal/mol, 3

735 hydrogen bonds (Gln503, Trp435, Asp433) are formed between PalGly and Chain C of hTRPC5,

736 and 10 hydrophobic interactions (Chain C: Trp435, Met438, Ala441, Ile484, Ile487, Leu491,


737 Leu514, Leu488; Chain D: Thr603, Thr607) are formed. The normalized agonizing effect of

738 PalGly is presented in (B), ML204 is a selective TRPC4/TRPC5 channel inhibitor (≥ 3 cells from

739 3 dishes, paired t-test). (C) Normalized stimulation curve of PalGly combining rosiglitazone, a

740 TRPC5 activator (≥ 5 cells from 3 dishes). The top two panels are representative recordings of

741 hTRPC5 current, outward current is in blue, and inward current is in green.



742

743 Figure 5. PalGly shortens action potential duration and QT interval


744 (A) APD traits of isolated primary rabbit ventricular cardiomyocytes before and after PalGly

745 administration (n = 8 from 3 rabbits, paired t-test), representative recording is on the left. (B) ECG

746 and APD traits of isolated Langendorff-perfused rabbit hearts (n = 8, paired t-test), representative

747 ECG recording is on the top left and APD recording on the bottom right. APA: action potential

748 amplitude. APD: action potential duration.




749

750 Figure 6. PalGly alters the transcriptomic and lipidomic profile of neonatal rat cardiomyocytes

751 (A) Volcano plot and heatmap of differential lipids. (B) LIPEA lipids enrichment. (C) Significant

752 differential expressed genes. (D) GO and KEGG enrichment. (E) GSEA analysis, GO categories

753 are on the left and middle, and KEGG categories are on the right.




754


755 Figure. S1 Circulating protein levels affect genetically proxied ECG morphology. Top

756 cis-pQTLs were selected to represent the expression of the specific proteins


757




A




B


















C

















medRxiv preprint doi: <https://doi.org/10.1101/2024.10.21.24315897>; this version posted October 22, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY-NC-ND 4.0 International license](https://creativecommons.org/licenses/by-nc-nd/4.0/).






medRxiv preprint doi: <https://doi.org/10.1101/2024.10.21.24315897>; this version posted October 22, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY-NC-ND 4.0 International license](https://creativecommons.org/licenses/by-nc-nd/4.0/).




A**B**


A




B



C



D



E

